Abstract

Long-term Outcomes of Biologics vs. Traditional DMARDs in Ankylosing Spondylitis

Author(s): Rani Silva*

Ankylosing spondylitis (AS) is a chronic inflammatory arthritis primarily affecting the axial skeleton, often leading to significant disability if not adequately managed. Traditional disease-modifying antirheumatic drugs (DMARDs) have been used for treatment, but biologic agents have emerged as effective alternatives. Long-term data comparing the outcomes of biologics versus traditional DMARDs are crucial for optimizing treatment strategies. This study aims to compare the long-term outcomes of biologic therapies versus traditional DMARDs in patients with ankylosing spondylitis, focusing on disease activity, functional status, and quality of life. We conducted a systematic review and meta-analysis of studies comparing long-term outcomes of biologics and traditional DMARDs in AS. Data were extracted from randomized controlled trials (RCTs), cohort studies, and observational studies, assessing measures such as disease activity scores, functional indices, and quality of life assessments. Biologic therapies, particularly tumor necrosis factor-alpha (TNF-α) inhibitors, demonstrated superior long-term outcomes compared to traditional DMARDs. Patients receiving biologics showed significant improvements in disease activity, spinal mobility, and quality of life. Traditional DMARDs, while beneficial, were less effective in controlling disease over the long term. Biologic therapies offer enhanced long-term outcomes in ankylosing spondylitis compared to traditional DMARDs. They provide more effective disease control, better functional outcomes, and improved quality of life. These findings support the use of biologics in the long-term management of AS, although treatment decisions should consider individual patient characteristics and preferences.